- Home
- AVXL vs MYGN Comparison
AVXL vs MYGN Comparison
Compare AVXL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- MYGN
- Stock Information
- Founded
- AVXL 2004
- MYGN 1991
- Country
- AVXL United States
- MYGN United States
- Employees
- AVXL N/A
- MYGN N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AVXL Health Care
- MYGN Health Care
- Exchange
- AVXL Nasdaq
- MYGN Nasdaq
- Market Cap
- AVXL 635.6M
- MYGN 625.5M
- IPO Year
- AVXL N/A
- MYGN 1995
- Fundamental
- Price
- AVXL $3.71
- MYGN $6.80
- Analyst Decision
- AVXL Strong Buy
- MYGN Hold
- Analyst Count
- AVXL 3
- MYGN 14
- Target Price
- AVXL $33.00
- MYGN $13.23
- AVG Volume (30 Days)
- AVXL 2.9M
- MYGN 1.1M
- Earning Date
- AVXL 12-22-2025
- MYGN 11-03-2025
- Dividend Yield
- AVXL N/A
- MYGN N/A
- EPS Growth
- AVXL N/A
- MYGN N/A
- EPS
- AVXL N/A
- MYGN N/A
- Revenue
- AVXL N/A
- MYGN $825,300,000.00
- Revenue This Year
- AVXL N/A
- MYGN $0.06
- Revenue Next Year
- AVXL N/A
- MYGN $5.68
- P/E Ratio
- AVXL N/A
- MYGN N/A
- Revenue Growth
- AVXL N/A
- MYGN 0.21
- 52 Week Low
- AVXL $2.86
- MYGN $3.76
- 52 Week High
- AVXL $14.44
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- AVXL 14.26
- MYGN 43.04
- Support Level
- AVXL $6.35
- MYGN $6.10
- Resistance Level
- AVXL $7.25
- MYGN $8.38
- Average True Range (ATR)
- AVXL 0.64
- MYGN 0.43
- MACD
- AVXL -0.34
- MYGN -0.11
- Stochastic Oscillator
- AVXL 14.49
- MYGN 28.73
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.